These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

816 related articles for article (PubMed ID: 15805248)

  • 1. PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma.
    Saal LH; Holm K; Maurer M; Memeo L; Su T; Wang X; Yu JS; Malmström PO; Mansukhani M; Enoksson J; Hibshoosh H; Borg A; Parsons R
    Cancer Res; 2005 Apr; 65(7):2554-9. PubMed ID: 15805248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the association of PIK3CA mutations and PTEN loss with efficacy of trastuzumab therapy in metastatic breast cancer.
    Razis E; Bobos M; Kotoula V; Eleftheraki AG; Kalofonos HP; Pavlakis K; Papakostas P; Aravantinos G; Rigakos G; Efstratiou I; Petraki K; Bafaloukos D; Kostopoulos I; Pectasides D; Kalogeras KT; Skarlos D; Fountzilas G
    Breast Cancer Res Treat; 2011 Jul; 128(2):447-56. PubMed ID: 21594665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer.
    Pérez-Tenorio G; Alkhori L; Olsson B; Waltersson MA; Nordenskjöld B; Rutqvist LE; Skoog L; Stål O
    Clin Cancer Res; 2007 Jun; 13(12):3577-84. PubMed ID: 17575221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer.
    Sueta A; Yamamoto Y; Yamamoto-Ibusuki M; Hayashi M; Takeshita T; Yamamoto S; Iwase H
    PLoS One; 2014; 9(12):e116054. PubMed ID: 25542038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correlation between activation of PI3K/AKT/mTOR pathway and prognosis of breast cancer in Chinese women.
    Deng L; Chen J; Zhong XR; Luo T; Wang YP; Huang HF; Yin LJ; Qiu Y; Bu H; Lv Q; Zheng H
    PLoS One; 2015; 10(3):e0120511. PubMed ID: 25816324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of somatic PI3K pathway and ERBB family mutations on pathological complete response (pCR) in HER2-positive breast cancer patients who received neoadjuvant HER2-targeted therapies.
    Toomey S; Eustace AJ; Fay J; Sheehan KM; Carr A; Milewska M; Madden SF; Teiserskiene A; Kay EW; O'Donovan N; Gallagher W; Grogan L; Breathnach O; Walshe J; Kelly C; Moulton B; Kennedy MJ; Gullo G; Hill AD; Power C; Duke D; Hambly N; Crown J; Hennessy BT
    Breast Cancer Res; 2017 Jul; 19(1):87. PubMed ID: 28750640
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Frequent monoallelic deletion of PTEN and its reciprocal associatioin with PIK3CA amplification in gastric carcinoma.
    Byun DS; Cho K; Ryu BK; Lee MG; Park JI; Chae KS; Kim HJ; Chi SG
    Int J Cancer; 2003 Apr; 104(3):318-27. PubMed ID: 12569555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
    Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
    JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
    Gonzalez-Angulo AM; Ferrer-Lozano J; Stemke-Hale K; Sahin A; Liu S; Barrera JA; Burgues O; Lluch AM; Chen H; Hortobagyi GN; Mills GB; Meric-Bernstam F
    Mol Cancer Ther; 2011 Jun; 10(6):1093-101. PubMed ID: 21490305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients.
    Chen L; Yang L; Yao L; Kuang XY; Zuo WJ; Li S; Qiao F; Liu YR; Cao ZG; Zhou SL; Zhou XY; Yang WT; Shi JX; Huang W; Hu X; Shao ZM
    Nat Commun; 2018 Apr; 9(1):1357. PubMed ID: 29636477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.
    Oda K; Okada J; Timmerman L; Rodriguez-Viciana P; Stokoe D; Shoji K; Taketani Y; Kuramoto H; Knight ZA; Shokat KM; McCormick F
    Cancer Res; 2008 Oct; 68(19):8127-36. PubMed ID: 18829572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer.
    Chandarlapaty S; Sakr RA; Giri D; Patil S; Heguy A; Morrow M; Modi S; Norton L; Rosen N; Hudis C; King TA
    Clin Cancer Res; 2012 Dec; 18(24):6784-91. PubMed ID: 23092874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysregulated PTEN-PKB and negative receptor status in human breast cancer.
    Shi W; Zhang X; Pintilie M; Ma N; Miller N; Banerjee D; Tsao MS; Mak T; Fyles A; Liu FF
    Int J Cancer; 2003 Mar; 104(2):195-203. PubMed ID: 12569575
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma.
    Tokunaga E; Oki E; Kimura Y; Yamanaka T; Egashira A; Nishida K; Koga T; Morita M; Kakeji Y; Maehara Y
    Breast Cancer Res Treat; 2007 Mar; 101(3):249-57. PubMed ID: 17006756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 regulates cell survival by inhibiting PIK3CA in squamous cell carcinomas.
    Singh B; Reddy PG; Goberdhan A; Walsh C; Dao S; Ngai I; Chou TC; O-Charoenrat P; Levine AJ; Rao PH; Stoffel A
    Genes Dev; 2002 Apr; 16(8):984-93. PubMed ID: 11959846
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
    Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
    Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Opposite Prognostic Impact of Single PTEN-loss and
    Lazaridis G; Kotoula V; Vrettou E; Kostopoulos I; Manousou K; Papadopoulou K; Giannoulatou E; Bobos M; Sotiropoulou M; Pentheroudakis G; Efstratiou I; Papoudou-Bai A; Psyrri A; Christodoulou C; Gogas H; Koutras A; Timotheadou E; Pectasides D; Zagouri F; Fountzilas G
    Cancer Genomics Proteomics; 2019; 16(3):195-206. PubMed ID: 31018950
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations.
    Velasco A; Bussaglia E; Pallares J; Dolcet X; Llobet D; Encinas M; Llecha N; Palacios J; Prat J; Matias-Guiu X
    Hum Pathol; 2006 Nov; 37(11):1465-72. PubMed ID: 16949921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
    Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups.
    Cizkova M; Susini A; Vacher S; Cizeron-Clairac G; Andrieu C; Driouch K; Fourme E; Lidereau R; Bièche I
    Breast Cancer Res; 2012 Feb; 14(1):R28. PubMed ID: 22330809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.